U.S. markets closed
  • S&P Futures

    4,229.75
    +4.50 (+0.11%)
     
  • Dow Futures

    34,717.00
    +31.00 (+0.09%)
     
  • Nasdaq Futures

    13,737.25
    +27.50 (+0.20%)
     
  • Russell 2000 Futures

    2,268.90
    +1.00 (+0.04%)
     
  • Crude Oil

    65.42
    +0.52 (+0.80%)
     
  • Gold

    1,835.80
    +4.50 (+0.25%)
     
  • Silver

    27.68
    +0.21 (+0.76%)
     
  • EUR/USD

    1.2179
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.5770
    +0.0160 (+1.02%)
     
  • Vix

    16.69
    -1.70 (-9.24%)
     
  • GBP/USD

    1.4036
    +0.0047 (+0.33%)
     
  • USD/JPY

    108.4890
    -0.0930 (-0.09%)
     
  • BTC-USD

    58,225.50
    -347.37 (-0.59%)
     
  • CMC Crypto 200

    1,480.07
    +44.29 (+3.08%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,357.82
    +26.42 (+0.09%)
     

Paratek (PRTK) Moves 14.5% Higher: Will This Strength Last?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Paratek Pharmaceuticals PRTK shares rallied 14.5% in the last trading session to close at $7.96. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% loss over the past four weeks.

Shares continue to gain as investors are optimistic on Nuzyra's growth trajectory.

Price and Consensus

Price Consensus Chart for PRTK
Price Consensus Chart for PRTK

This pharmaceutical company is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of +66.7%. Revenues are expected to be $32.83 million, up 314.5% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Paratek, the consensus EPS estimate for the quarter has been revised 5.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on PRTK going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Paratek Pharmaceuticals, Inc. (PRTK) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research